ARTICLE | Clinical News
Bamosiran: Phase II data
October 12, 2015 7:00 AM UTC
Top-line data from the double-blind, international Phase II SYLTAG trial in 184 patients with open-angle glaucoma or ocular hypertension and a baseline IOP of >=23 mmHg showed that once-daily 0.375%, ...